Floatz logo

Gozetotide

Metastatic Prostate Carcinoma

Small moleculeUnknownDormant
C
35/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
20/ 100
Competitive Position
81/ 100

Competitive context

229 Active assets in the Metastatic Prostate Carcinoma cohort.

Asset / SponsorPhaseRating
AXUMIN
VA Greater Los Angeles Healthcare System
Phase 4BBB
Leuporelin
Mayo Clinic
Phase 4BBB
Prednisone
Mayo Clinic
Phase 4BB
Abiraterone
Mayo Clinic
Phase 4BB
Pembrolizumab
CuraCell TX AB
Phase 2BB

View all 50 →

Same molecule, other indications

Gozetotide is also rated in:

prostate neoplasmActive
BB
Indicative · Phase 3
68 / 100
View asset →
prostate cancerActive
BB
Indicative · Phase 3
66 / 100
View asset →
prostate disorderDormant
D
Indicative · Unknown
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →